Aarti Drugs Ltd. (BSE: 524348) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹4,650 Cr, it ranks #866 by market cap among the 6,197 Indian listed companies on FinBizNet, and #28 of 86 in Medicinal Chemicals and Botanical Products. At ₹506.00 (as of 16 Nov 2026), the share price is 4.1% below its 52-week high of ₹527.50 and 58.6% above its 52-week low of ₹318.95. The share price is up 3.2% over one year and up 18.6% over three months.
| Current Price | ₹506.00 |
|---|---|
| Market Cap | ₹4,650 Cr |
| BSE Code | 524348 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 23.9 |
| Return on Equity | 13.36% |
| Return on Assets | 5.62% |
| 52-Week Range | ₹318.95 – ₹527.50 |
| 1-Year Price Change | +3.2% |
| 3-Month Price Change | +18.6% |
| Beta (1Y) | 0.23 |
| Dividend Yield | 0.39% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.aartidrugs.co.in |
| Revenue | ₹826 Cr |
|---|---|
| Net Profit | ₹83 Cr |
| Net Margin | 10.0% |
| EPS (Basic) | ₹9.07 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Aarti Drugs Ltd. reported revenue of ₹826 Cr in Q2 FY27, up 26.6% from ₹653 Cr in Q2 FY26 and up 17.6% from ₹703 Cr in Q1 FY27. It posted a net profit of ₹83 Cr for the quarter, against a net profit of ₹45 Cr in Q2 FY26 (up 83.3%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹591 Cr (Q1 FY26) to ₹826 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹826 Cr | ₹83 Cr | 10.0% |
| Q1 FY27 | ₹703 Cr | ₹50 Cr | 7.1% |
| Q4 FY26 | ₹720 Cr | ₹55 Cr | 7.7% |
| Q3 FY26 | ₹602 Cr | ₹41 Cr | 6.7% |
| Q2 FY26 | ₹653 Cr | ₹45 Cr | 6.9% |
| Q1 FY26 | ₹591 Cr | ₹54 Cr | 9.1% |
| Q4 FY25 | ₹677 Cr | ₹63 Cr | 9.3% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 54.07% of Aarti Drugs Ltd.'s shares as of Sept 2026, against 54.72% in Sept 2025 (−0.65 percentage points). Delivery averaged 32.5% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enrofloxacin base, gatifloxacin sesquihydrate, levofloxacin base, norfloxacin, ofloxacin, metronidazole, metronidazole benzoate, ornidazole, secnidazole, tinidazole, clopidogrel bisulphate, ticlopidine HCL, metformin HCL, pioglitazone HCL, teneligliptin, vildagliptin, fluconazole, ketoconazole, tolnaftate, zolpidem tartrate, niacin, raloxifene HCL, and acamprosate. It also provides benzene sulphonyl chloride, benzene sulphonic acid, methyl benzenesulfonate, sodium benzene sulfinate, para toluene sulphonyl chloride, methyl para toluenesulfonate, sodium para toluenesulfinate, para chlorobenzenesulfon
1. Bulk Drugs-This segment manufactures and sells active pharmaceutical ingredients. 2. Others-This segment engages in the manufacture and sale of bulk drugs and its intermediates. 3. Pharmaceuticals-0
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Aarti Drugs Ltd. | ₹4,650 Cr | 23.9 | 13.36% | ₹826 Cr | +3.2% |
Listed by market capitalisation. Ratios are shown for context only.
Aarti Drugs Ltd. is trading at ₹506.00, with a market capitalisation of ₹4,650 Cr.
Aarti Drugs Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Aarti Drugs Ltd. has a P/E of 23.9 and a return on equity of 13.36%.
Aarti Drugs Ltd. is listed on the BSE under the scrip code 524348.
Aarti Drugs Ltd.'s share price is up 3.2% over one year and up 18.6% over three months. Its 52-week range is ₹318.95 to ₹527.50.
In Q2 FY27, Aarti Drugs Ltd. reported revenue of ₹826 Cr and net profit of ₹83 Cr, with basic EPS of ₹9.07 (consolidated, parsed from the company's exchange filing).
Aarti Drugs Ltd. reported revenue of ₹826 Cr in Q2 FY27, up 26.6% from ₹653 Cr in Q2 FY26 and up 17.6% from ₹703 Cr in Q1 FY27.
Promoters held 54.07% of Aarti Drugs Ltd.'s shares as of Sept 2026, against 54.72% in Sept 2025 (−0.65 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.